Golimumab (Simponi Aria)

Simponi Aria (golimumab) is covered only for FDA‑approved adult indications (moderately to severely active rheumatoid arthritis, active psoriatic arthritis, and active ankylosing spondylitis) with IV dosing limited to up to 2 mg/kg at weeks 0 and 4 then no more frequently than every 8 weeks (non‑FDA uses excluded). Initial approval (3 months) requires prescription by or consultation with the appropriate specialist (RA/AS: rheumatologist; PsA: rheumatologist or dermatologist) and for RA a documented 3‑month trial of at least one biologic or one conventional synthetic DMARD; renewals are 12 months contingent on documented clinical response and meeting applicable safety/documentation requirements.

"Simponi Aria is indicated for the treatment of adult patients with active psoriatic arthritis."

Sign up to see full coverage criteria, indications, and limitations.